8,456 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.
2013 / Double-blind, randomized, placebo-controlled clinical trial
Ninety postmenopausal women were randomized to receive 4% isoflavone vaginal gel (1 g/day), placebo gel, or conjugated equine estrogen cream (0.3 mg/day) for 12 weeks. Isoflavone vaginal gel was effective for relieving vaginal dryness and dyspareunia symptoms and increased intermediate and superficial cells, showing results similar to conjugated equine estrogens and superior to placebo. No changes in endometrial thickness, serum FSH, or estradiol levels were observed at the study endpoint.
Lima SM, Yamada SS, Reis BF, et al. Maturitas, 2013. PMID 23312487
2013 / Prospective, placebo-controlled, double-blind, randomized trial
One hundred and twenty individuals with presbyacusis were randomized into four groups to receive ginkgo biloba dry extract, alpha-lipoic acid plus vitamin C, papaverine chlorhydrate plus vitamin E, or placebo for six months. Participants were evaluated at recruitment and after six months using pure tone audiometry, speech recognition threshold, and percentage index of speech recognition. The various treatments had no effect on any evaluated measures of hearing, either between groups or over time, with no statistically significant changes observed in hearing thresholds.
Polanski JF, Cruz OL J Laryngol Otol, 2013. PMID 23318104
2013 / Randomized, controlled, double-blind, parallel-group trial
Twenty-four healthy older adults were randomized to receive either 3 g/day of Ca-HMB or an inactive placebo starting 5 days before 10 days of complete bed rest through an 8-week rehabilitation phase. In 19 evaluable subjects, bed rest caused a significant decrease in total lean body mass in the control group (-2.05 ± 0.66 kg; p = 0.02), whereas HMB prevented the decline (-0.17 ± 0.19 kg; p = 0.23, excluding one subject), resulting in a significant difference between groups (p = 0.02). Differences in functional parameters were not observed, likely due to the small sample size.
Deutz NE, Pereira SL, Hays NP, et al. Clin Nutr, 2013. PMID 23514626
2013 / Randomized controlled trial
In a randomized controlled trial of elderly adults with mild cognitive impairment over two years, daily high-dose B vitamins (0.8 mg folic acid, 20 mg B6, 0.5 mg B12) slowed whole-brain shrinkage and reduced gray matter atrophy in Alzheimer-vulnerable regions up to sevenfold. This protective effect was restricted to participants with baseline homocysteine levels above 11 micromol/L. In that subgroup, B-vitamin therapy countered the rapid gray matter loss linked to elevated homocysteine.
Douaud G, Refsum H, de Jager CA, et al. Proc Natl Acad Sci U S A, 2013. PMID 23690582
2013 / Randomized controlled trial
Participants were randomly assigned to 4 groups combining daily or discretionary sunscreen use with either 30 mg of beta-carotene or placebo. After 4.5 years, the daily sunscreen group demonstrated no detectable increase in skin aging and 24% less skin aging compared with the discretionary group (relative odds, 0.76 [95% CI, 0.59 to 0.98]). Beta-carotene supplementation showed no overall effect on skin aging, though contrasting associations appeared across baseline severity subgroups. Limitations noted include missing outcome data and modest statistical power to detect moderate treatment effects.
Hughes MC, Williams GM, Baker P, et al. Ann Intern Med, 2013. PMID 23732711
2013 / Randomized controlled trial
Twenty-seven inactive older men underwent eight weeks of exercise training combined with 250 mg daily trans-resveratrol or placebo. Exercise raised maximal oxygen uptake 45% more in the placebo group than the resveratrol group (P < 0.05) and lowered mean arterial pressure only with placebo (-4.8 ± 1.7 mmHg, P < 0.05). Resveratrol also blunted exercise-related improvements in blood triglycerides and low-density lipoprotein, while Sirtuin 1 protein levels remained unaffected.
Gliemann L, Schmidt JF, Olesen J, et al. J Physiol, 2013. PMID 23878368
2013 / Randomized controlled trial
A randomized, double-blind, placebo-controlled trial tested 300 mg/day of Mekabu fucoidan versus placebo for 4 weeks before trivalent influenza vaccination in 70 older Japanese adults. The fucoidan group developed higher antibody titers against all three vaccine strains. Antibody increases against the B strain met licensure criteria in the fucoidan group (geometric mean titer ratio 2.4) but not placebo (1.7).
Negishi H, Mori M, Mori H, et al. J Nutr, 2013. PMID 24005608
2013 / Follow-up comparative pilot study
This pilot study compared 10 men undergoing a 5-year comprehensive lifestyle intervention (diet, activity, stress management, social support) with 25 external controls on active surveillance. At 5 years, relative telomere length increased from baseline by a median of 0.06 T/S units (IQR -0.05 to 0.11) in the intervention group and decreased by -0.03 T/S units (-0.05 to 0.03) in controls (p=0.03). Combined data showed each percentage point increase in lifestyle adherence score was associated with a 0.07 increase in T/S units (95% CI 0.02-0.12, p=0.005). Telomerase activity decreased in both groups (intervention: -0.25 units; controls: -1.08 units; p=0.64) and did not significantly associate with lifestyle adherence.
Ornish D, Lin J, Chan JM, et al. Lancet Oncol, 2013. PMID 24051140
2013 / Comparative intervention trial
Sixty-five older adults were divided into four groups for 12 weeks: Nordic walking, conventional walking, band-based resistance exercise, or a control group. Upper-body strength improved significantly in the resistance (22.3%) and Nordic walking (11.6%) groups compared to conventional walking and controls. Cardio-respiratory fitness improved more in the Nordic walking (10.9%) and conventional walking (10.6%) groups than in the resistance and control groups, while upper- and lower-body flexibility improved in all exercise groups. None of the groups showed improvements in balance measures.
Takeshima N, Islam MM, Rogers ME, et al. J Sports Sci Med, 2013. PMID 24149147
2013 / Randomized, double-blind, placebo-controlled trial
In the Physicians' Health Study II, 5,947 male physicians aged 65 years or older were randomized to receive a daily multivitamin or placebo, with up to 4 repeated cognitive telephone assessments completed over 12 years. No difference was observed in mean cognitive change over time between groups for the global composite score (mean difference, -0.01 SU; 95% CI, -0.04 to 0.02 SU) or verbal memory (mean difference, -0.005 SU; 95% CI, -0.04 to 0.03 SU). Limitations noted were that vitamin doses may have been too low or the population too well-nourished to see a benefit.
Grodstein F, O'Brien J, Kang JH, et al. Ann Intern Med, 2013. PMID 24490265
2013 / Interventional trial with three groups
Sixty-seven elderly women were assigned to a Nordic walking group (n=21), a normal walking group (n=21), or a control group (n=25) for 12 weeks, with walking sessions performed three times per week. Significant differences between groups were observed for weight (F=8.07, p<.001), grip strength (F=10.30, p<.001), sit to stand (F=16.84, p<.001), arm curl (F=41.16, p<.001), and total cholesterol (F=5.14, p=.009). Arm curl performance was significantly increased in the Nordic walking group compared to the normal walking and control groups.
Song MS, Yoo YK, Choi CH, et al. Asian Nurs Res (Korean Soc Nurs Sci), 2013. PMID 25031209
2012 / Cluster randomized controlled trial
A cluster randomized trial across 51 care facilities assigned 602 older adults (mean age 86.4 years) to daily early-morning sunlight, sunlight with calcium (600 mg/day), or control for one year. Overall adherence was low at a median of 26%, and intention-to-treat analysis showed no effect on fall risk (IRR 1.06; 95% CI, 0.76-1.48; P = 0.73). However, attending at least 130 sunlight sessions was linked to significantly fewer falls (IRR 0.52; 95% CI, 0.31-0.88).
Sambrook PN, Cameron ID, Chen JS, et al. Osteoporos Int, 2012. PMID 21369788
2012 / Randomized controlled trial
A randomized trial assigned 120 elderly participants (mean age 70.1 years) to 300,000 IU of vitamin D or placebo administered orally or intramuscularly. At four weeks, both routes of vitamin D significantly reduced parathyroid hormone (P = 0.0001) and raised vitamin D levels (P = 0.0001 for injection, P = 0.004 for oral). Both treated groups showed significant reductions in pain scores, improved mobility, and enhanced physical functioning.
Sakalli H, Arslan D, Yucel AE Rheumatol Int, 2012. PMID 21556746
2012 / Randomized crossover trial
A randomized, placebo-controlled crossover study tested dried rosemary leaf powder at four doses in 28 older adults (mean age 75 years). The lowest dose of 750 mg improved memory speed relative to placebo (P = .01), whereas the highest dose of 6,000 mg impaired performance (P < .01). Significant deleterious effects also appeared on other cognitive measures, though these were less consistent.
Pengelly A, Snow J, Mills SY, et al. J Med Food, 2012. PMID 21877951
2012 / Randomized, double-blind, placebo-controlled trial
A 12-week randomized, double-blind, placebo-controlled trial evaluated natural S-equol supplementation (10 mg/day [EQL10], 30 mg/day [EQL30], or placebo) in 101 equol-nonproducing postmenopausal Japanese women. Both EQL10 and EQL30 groups demonstrated significant reductions in wrinkle area compared with the placebo group (P < 0.05). In addition, wrinkle depth was significantly reduced in the EQL30 group compared with placebo (P < 0.05), while other skin parameters showed no significant differences among groups. No abnormal findings were detected in hormone status or gynecological examinations.
Oyama A, Ueno T, Uchiyama S, et al. Menopause, 2012. PMID 21934634
2012 / Randomized controlled trial
In a randomized, double-blind, placebo-controlled trial, 2,911 coronary patients aged 60 to 80 years received margarines delivering 400 mg/day EPA-DHA, 2 g/day ALA, both, or placebo for 40 months. Changes in Mini-Mental State Examination scores did not differ between EPA-DHA and placebo (-0.65 vs -0.69 points, P = .44) or ALA and placebo (-0.60 vs -0.74 points, P = .12). Risk of cognitive decline was 1.03 (95% CI: 0.84-1.26) for EPA-DHA and 0.90 (95% CI: 0.74-1.10) for ALA.
Geleijnse JM, Giltay EJ, Kromhout D Alzheimers Dement, 2012. PMID 21967845
2012 / Randomized placebo-controlled trial
Older adults with mild cognitive impairment received Concord grape juice or a placebo drink for 16 weeks. Grape juice consumption decreased semantic interference during memory assessments. Functional neuroimaging also revealed heightened neural responses in both anterior and posterior areas of the right hemisphere among participants who received the grape juice treatment.
Krikorian R, Boespflug EL, Fleck DE, et al. J Agric Food Chem, 2012. PMID 22468945
2012 / Randomized controlled trial follow-up
Researchers evaluated leukocyte telomere length (TL) at two time points on average 4.5 years apart in the Finnish Diabetes Prevention Study (N=334 and 343). TL was inversely correlated with age and increased in about two thirds of individuals in both the intervention and control groups, increasing most in those with the shortest baseline TL. The lifestyle intervention had no effect on TL, and TL was not associated with the development of type 2 diabetes, insulin secretion, or insulin resistance indices.
Hovatta I, de Mello VD, Kananen L, et al. PLoS One, 2012. PMID 22493726
2012 / Secondary analysis of a randomized controlled trial
This study evaluated 17,473 postmenopausal women in the Women's Health Initiative Dietary Modification trial to determine the effects of a diet low in fat and high in fruit, vegetables, and whole grains, along with weight loss, on vasomotor symptoms (VMS). Assignment to the dietary intervention versus control was associated with a higher likelihood of symptom elimination (OR 1.14; 95% CI, 1.01-1.28). Women who lost 10 lb or more (OR 1.23; 95% CI, 1.05-1.46) or 10% or more of baseline weight (OR 1.56; 95% CI, 1.21-2.02) were more likely to eliminate VMS compared with those who maintained weight. Large weight loss (>22 lb), but not dietary changes, was linked to the elimination of moderate/severe VMS.
Kroenke CH, Caan BJ, Stefanick ML, et al. Menopause, 2012. PMID 22781782
2012 / Longitudinal, interventional open-label study
Twenty-nine patients with early age-related macular degeneration received oral saffron supplementation (20 mg/day) over an average follow-up of 14 (±2) months. After three months of supplementation, mean fERG sensitivity improved by 0.3 log units compared to baseline (P < 0.01), and mean visual acuity improved by two Snellen lines from 0.75 to 0.9 (P < 0.01). These changes remained stable throughout the follow-up period.
Piccardi M, Marangoni D, Minnella AM, et al. Evid Based Complement Alternat Med, 2012. PMID 22852021
2012 / Randomized crossover trial
A randomized crossover trial evaluated the effects of 2 months of a pulse-based diet (two servings daily of beans, chickpeas, peas, or lentils; ~150 g/d dry weight) versus a regular diet, separated by a 1-month washout, in older adults. Compared with the regular diet, the pulse diet decreased total cholesterol by 8.3% (from 4.57 to 4.11 mmol/l vs. 4.47 to 4.39 mmol/l; P < 0.001) and LDL-C by 7.9% (from 2.93 to 2.55 mmol/l vs. 2.96 to 2.81 mmol/l; P = 0.01). In a sub-analysis of 20 participants with high baseline cholesterol, the pulse diet reduced cholesterol by 6% compared to the regular diet (from 5.62 to 5.26 mmol/l vs. 5.60 to 5.57 mmol/l; P = 0.05).
Abeysekara S, Chilibeck PD, Vatanparast H, et al. Br J Nutr, 2012. PMID 22916805
2012 / Randomized, parallel-group, double-blind, placebo-controlled trial
In the GuidAge trial, 2,854 adults aged 70 years or older with memory complaints were randomly allocated to receive 120 mg standardized Ginkgo biloba extract (EGb761) twice daily or placebo for 5 years. By 5 years, probable Alzheimer's disease was diagnosed in 61 participants in the ginkgo group (1.2 cases per 100 person-years) versus 73 in the placebo group (1.4 cases per 100 person-years; HR 0.84, 95% CI 0.60-1.18; p=0.306). Incidence of adverse events, all-cause deaths (76 vs 82; p=0.68), stroke (65 vs 60; RR 1.12, 95% CI 0.77-1.63; p=0.57), and other hemorrhagic or cardiovascular events did not differ significantly between groups.
Vellas B, Coley N, Ousset PJ, et al. Lancet Neurol, 2012. PMID 22959217
2012 / Randomized, double-blind, placebo-controlled trial
Thirty-six individuals with mild-to-moderate Alzheimer's disease were randomized to receive placebo, 2 g/day, or 4 g/day of oral Curcumin C3 Complex for 24 weeks. Curcumin was generally well-tolerated, though 3 of 24 participants in the curcumin group withdrew due to gastrointestinal symptoms. Curcumin was linked to clinically insignificant lowered hematocrit and increased glucose levels. No differences between treatment groups were observed in clinical cognitive outcomes or biomarker efficacy measures, with low levels of native curcumin measured in plasma (7.32 ng/mL).
Ringman JM, Frautschy SA, Teng E, et al. Alzheimers Res Ther, 2012. PMID 23107780
2012 / Randomized controlled trial
A randomized trial in 83 older adults consuming two or fewer daily portions of fruits and vegetables evaluated the effect of consuming at least five portions daily for 16 weeks. Following vaccination at 12 weeks, the five-portion group demonstrated a greater pneumococcal antibody ratio from baseline (geometric mean 3.1; 95% CI: 2.1, 4.4) than the two-portion group (1.7; 95% CI: 1.3, 2.1; P = 0.005). Responses to tetanus toxoid showed no significant group difference.
Gibson A, Edgar JD, Neville CE, et al. Am J Clin Nutr, 2012. PMID 23134881